Bannerbild German Brest Group

ESMO 2019

13.03.2018

ESMO 2019

ESMO Breast Cancer is an annual congress taking place for the first time on 2-4 May 2019 in Berlin, Germany.
Brought to you by ESMO, your trusted provider of specialised education in oncology.

More Information

News

  • 04.06.2018 ASCO: GeparNuevo Presentation

    GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.

    Mehr ...
  • 31.05.2018 Paper of the month: elderly women and neoadjuvant chemotherapy

    A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.

    Mehr ...
  • 30.04.2018 Paper of the month: survival analysis of the GeparQuinto trial

    We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.

    Mehr ...
  • 30.03.2018 Paper of the month: March 2018

    An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd